Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy.

IF 1.8 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Maternal and Child Health Journal Pub Date : 2025-05-01 Epub Date: 2025-04-26 DOI:10.1007/s10995-025-04091-w

Hannah Yang, Yosra Elsayed, Victoria Zablocki, Beth Bailey

{"title":"Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy.","authors":"Hannah Yang, Yosra Elsayed, Victoria Zablocki, Beth Bailey","doi":"10.1007/s10995-025-04091-w","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of this pilot study was to examine, using observational data, birth outcomes following the use of antiviral therapy in pregnancy.Methods: This retrospective chart review study involved patients diagnosed with COVID-19 who received care at a single university-affiliated obstetrics practice grouped as having received, or not received, Ritonavir-Boosted Nirmatrelvir (NMV-r). Participant background information and birth outcomes were extracted and analyzed.Results: Of 141 patients, nine were prescribed and took a course of NMV-r. Infants born to patients who were pregnantand took NMV-r had significantly shorter hospital stays (average of 2.5 days less) compared to infants born to patients who did not take NMV-r. In addition, there were multiple non-significant but clinically meaningful group differences: more than 10% of those who did not take NMV-r delivered preterm, while all those who took NMV-r delivered after 37 weeks, and infants born to those who did not take NMV-r were three times more likely to be admitted to the NICU compared to infants born to those who took a course of NMV-r.Conclusion: Patients who are pregnant andtake NMV-r as treatment for COVID-19 appear to have better birth outcomes than those who do not, with no identified adverse effects in this small convenience sample. Based on this pilot study, NMV-r may improve clinical outcomes for obstetrics patients who contract COVID-19 during pregnancy.","PeriodicalId":48367,"journal":{"name":"Maternal and Child Health Journal","volume":" ","pages":"599-603"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Maternal and Child Health Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10995-025-04091-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of this pilot study was to examine, using observational data, birth outcomes following the use of antiviral therapy in pregnancy.

Methods: This retrospective chart review study involved patients diagnosed with COVID-19 who received care at a single university-affiliated obstetrics practice grouped as having received, or not received, Ritonavir-Boosted Nirmatrelvir (NMV-r). Participant background information and birth outcomes were extracted and analyzed.

Results: Of 141 patients, nine were prescribed and took a course of NMV-r. Infants born to patients who were pregnantand took NMV-r had significantly shorter hospital stays (average of 2.5 days less) compared to infants born to patients who did not take NMV-r. In addition, there were multiple non-significant but clinically meaningful group differences: more than 10% of those who did not take NMV-r delivered preterm, while all those who took NMV-r delivered after 37 weeks, and infants born to those who did not take NMV-r were three times more likely to be admitted to the NICU compared to infants born to those who took a course of NMV-r.

Conclusion: Patients who are pregnant andtake NMV-r as treatment for COVID-19 appear to have better birth outcomes than those who do not, with no identified adverse effects in this small convenience sample. Based on this pilot study, NMV-r may improve clinical outcomes for obstetrics patients who contract COVID-19 during pregnancy.

查看原文本刊更多论文

妊娠期抗病毒治疗治疗COVID-19后的出生结局

本初步研究的目的是使用观察性数据，检查妊娠期使用抗病毒治疗后的出生结局。方法：本回顾性图表回顾研究纳入了在单一大学附属产科诊所接受治疗的COVID-19患者，分为接受或未接受利托那韦增效尼马特韦（NMV-r）治疗。提取和分析参与者的背景信息和出生结果。结果：141例患者中，9例患者接受了NMV-r治疗。与未服用NMV-r的孕妇所生婴儿相比，服用NMV-r的孕妇所生婴儿的住院时间明显缩短（平均少2.5天）。此外，还有多个不显著但具有临床意义的组间差异：超过10%的未服用NMV-r的婴儿早产，而所有服用NMV-r的婴儿在37周后分娩，未服用NMV-r的婴儿与服用NMV-r疗程的婴儿相比，进入新生儿重症监护病房的可能性要高3倍。结论：在这个小样本中，孕妇服用NMV-r作为COVID-19治疗的患者似乎比不服用NMV-r的患者有更好的分娩结局，没有发现不良反应。根据这项初步研究，NMV-r可能会改善妊娠期感染COVID-19的产科患者的临床结局。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Maternal and Child Health Journal PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

3.20

自引率

4.30%

发文量

271

期刊介绍： Maternal and Child Health Journal is the first exclusive forum to advance the scientific and professional knowledge base of the maternal and child health (MCH) field. This bimonthly provides peer-reviewed papers addressing the following areas of MCH practice, policy, and research: MCH epidemiology, demography, and health status assessment Innovative MCH service initiatives Implementation of MCH programs MCH policy analysis and advocacy MCH professional development. Exploring the full spectrum of the MCH field, Maternal and Child Health Journal is an important tool for practitioners as well as academics in public health, obstetrics, gynecology, prenatal medicine, pediatrics, and neonatology. Sponsors include the Association of Maternal and Child Health Programs (AMCHP), the Association of Teachers of Maternal and Child Health (ATMCH), and CityMatCH.